PARP-1 improves leukemia outcomes by inducing parthanatos during chemotherapy.

Humans Apoptosis Cell Line Leukemia Leukocytes, Mononuclear Poly(ADP-ribose) Polymerase Inhibitors / pharmacology
NAD+ ADP-ribosyltransferase 1 PAR PARP-1 acute myelomonocytic and monocytic leukemia apoptosis cancer biology caspase-independent programmed cell death nucleoside analog poly(ADP-ribose) precision medicine prognostic blood test

Journal

Cell reports. Medicine
ISSN: 2666-3791
Titre abrégé: Cell Rep Med
Pays: United States
ID NLM: 101766894

Informations de publication

Date de publication:
19 09 2023
Historique:
received: 07 06 2021
revised: 13 02 2023
accepted: 16 08 2023
medline: 22 9 2023
pubmed: 9 9 2023
entrez: 8 9 2023
Statut: ppublish

Résumé

Previous chemotherapy research has focused almost exclusively on apoptosis. Here, a standard frontline drug combination of cytarabine and idarubicin induces distinct features of caspase-independent, poly(ADP-ribose) polymerase 1 (PARP-1)-mediated programmed cell death "parthanatos" in acute myeloid leukemia (AML) cell lines (n = 3/10 tested), peripheral blood mononuclear cells from healthy human donors (n = 10/10 tested), and primary cell samples from patients with AML (n = 18/39 tested, French-American-British subtypes M4 and M5). A 3-fold improvement in survival rates is observed in the parthanatos-positive versus -negative patient groups (hazard ratio [HR] = 0.28-0.37, p = 0.002-0.046). Manipulation of PARP-1 activity in parthanatos-competent cells reveals higher drug sensitivity in cells that have basal PARP-1 levels as compared with those subjected to PARP-1 overexpression or suppression. The same trends are observed in RNA expression databases and support the conclusion that PARP-1 can have optimal levels for favorable chemotherapeutic responses.

Identifiants

DOI: 10.1016/j.xcrm.2023.101191 PMID: 37683650 PMC: PMC10518631
pubmed: 37683650
pii: S2666-3791(23)00358-0
doi: 10.1016/j.xcrm.2023.101191
pmc: PMC10518631
pii:
doi:

Substances chimiques

Poly(ADP-ribose) Polymerase Inhibitors 0
PARP1 protein, human EC 2.4.2.30

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

101191

Subventions

Organisme : CIHR
Pays : Canada

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests A.M. is an employee of Lonza Group AG

Références

Mol Neurobiol. 2019 Jul;56(7):4760-4777
pubmed: 30387075
BMC Cancer. 2005 Jun 11;5:60
pubmed: 15949045
Ann Oncol. 2016 Aug;27(8):1474-81
pubmed: 27084953
Exp Ther Med. 2017 Aug;14(2):1081-1085
pubmed: 28810561
Oncotarget. 2015 Sep 29;6(29):27490-504
pubmed: 26314963
Leukemia. 2020 Mar;34(3):682-696
pubmed: 31919472
Cancer Discov. 2014 Mar;4(3):362-75
pubmed: 24346116
Front Biosci (Landmark Ed). 2009 Jan 01;14(3):1116-28
pubmed: 19273119
Sci Rep. 2017 Jan 23;7:41340
pubmed: 28112275
Leukemia. 1997 Sep;11(9):1469-77
pubmed: 9305600
Leukemia. 2019 Dec;33(12):2795-2804
pubmed: 31628431
Blood. 2003 Dec 1;102(12):4179-86
pubmed: 12920030
Cell Death Dis. 2019 Sep 9;10(9):650
pubmed: 31501419
Cancer Cell. 2017 Dec 11;32(6):748-760.e6
pubmed: 29232553
Ann N Y Acad Sci. 2008 Dec;1147:233-41
pubmed: 19076445
Exp Neurol. 2009 Aug;218(2):193-202
pubmed: 19332058
Nat Rev Cancer. 2003 Sep;3(9):650-65
pubmed: 12951584
Blood. 2017 Feb 2;129(5):547-552
pubmed: 27956388
J Immunol Methods. 2006 Jun 30;313(1-2):199-208
pubmed: 16756987
J Exp Clin Cancer Res. 2018 Dec 12;37(1):310
pubmed: 30541583
ACS Pharmacol Transl Sci. 2020 Oct 12;3(6):1225-1232
pubmed: 33344899
Nat Rev Clin Oncol. 2020 Jul;17(7):395-417
pubmed: 32203277
Proc Natl Acad Sci U S A. 2006 Nov 28;103(48):18308-13
pubmed: 17116882
Blood Cancer J. 2016 Jul 01;6(7):e441
pubmed: 27367478
Aging (Albany NY). 2021 Jan 20;13(3):4242-4257
pubmed: 33495407
Blood. 2010 Jan 21;115(3):453-74
pubmed: 19880497
Nucleic Acids Res. 2022 Jun 24;50(11):6313-6331
pubmed: 35648484
Leukemia. 2015 Feb;29(2):312-20
pubmed: 25113226
Sci Rep. 2020 May 20;10(1):8349
pubmed: 32433559
Br J Pharmacol. 2014 Apr;171(8):2000-16
pubmed: 24684389
Sci Signal. 2011 Apr 05;4(167):ra20
pubmed: 21467298
Front Cell Dev Biol. 2019 Mar 19;7:40
pubmed: 30941349
Nat Commun. 2019 Dec 11;10(1):5654
pubmed: 31827085
PLoS One. 2013 Nov 11;8(11):e79106
pubmed: 24244429
Nature. 2015 Feb 26;518(7540):552-555
pubmed: 25487151
Cell Death Differ. 2012 Jan;19(1):107-20
pubmed: 21760595
Nat Med. 2017 Feb;23(2):250-255
pubmed: 27991919
Clin Adv Hematol Oncol. 2019 Oct;17(10):569-575
pubmed: 31730583
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Cell. 2022 May 26;185(11):1943-1959.e21
pubmed: 35545089
Proc Natl Acad Sci U S A. 2018 Apr 24;115(17):E4061-E4070
pubmed: 29632181
J Clin Oncol. 1983 Dec;1(12):763-71
pubmed: 6668493
Oncotarget. 2019 Nov 19;10(62):6723-6738
pubmed: 31803365
Cancer Chemother Pharmacol. 1995;36(5):425-30
pubmed: 7634384
Oncogene. 2020 Jan;39(1):1-16
pubmed: 31462710
Am J Hematol. 2018 Oct;93(10):1267-1291
pubmed: 30328165
Proc Natl Acad Sci U S A. 2006 Nov 28;103(48):18314-9
pubmed: 17116881
Ann Oncol. 2012 May;23(5):1156-1164
pubmed: 21908496
Science. 2016 Oct 7;354(6308):
pubmed: 27846469
Proc Natl Acad Sci U S A. 2013 Nov 19;110(47):18964-9
pubmed: 24191052
Blood. 2015 Jul 16;126(3):291-9
pubmed: 25987659
Front Cell Dev Biol. 2020 Sep 09;8:564601
pubmed: 33015058
Proc Natl Acad Sci U S A. 2018 Feb 13;115(7):E1366-E1373
pubmed: 29378947
J Drug Assess. 2018 Jul 10;7(1):51-53
pubmed: 30034924
Genet Test Mol Biomarkers. 2018 Jun;22(6):343-349
pubmed: 29812960
BMC Cancer. 2020 May 18;20(1):435
pubmed: 32423430
Clin Cancer Res. 1995 Sep;1(9):1005-13
pubmed: 9816073
Blood. 2019 Jan 3;133(1):7-17
pubmed: 30361262
Br J Haematol. 2014 Feb;164(3):352-365
pubmed: 24236538
Sci Rep. 2017 Jun 23;7(1):4138
pubmed: 28646224
Future Oncol. 2015;11(5):747-57
pubmed: 25757679
J Cell Biol. 2014 Jun 9;205(5):613-9
pubmed: 24914234
Semin Cancer Biol. 2015 Dec;35 Suppl:S78-S103
pubmed: 25936818
Nature. 2013 Oct 17;502(7471):333-339
pubmed: 24132290
Cell Death Discov. 2018 Dec 5;4:111
pubmed: 30534419
Redox Biol. 2019 Sep;26:101239
pubmed: 31212216
Haematologica. 2008 Jan;93(1):67-74
pubmed: 18166787
Exp Hematol. 2001 Apr;29(4):448-57
pubmed: 11301185
Cancer Lett. 2019 Jul 10;454:171-178
pubmed: 30953707
EBioMedicine. 2018 Dec;38:47-56
pubmed: 30472087
Cell Death Differ. 2018 Mar;25(3):486-541
pubmed: 29362479
Apoptosis. 2006 Jan;11(1):131-9
pubmed: 16374543
Leukemia. 2012 Mar;26(3):554-7
pubmed: 21904384
Front Oncol. 2021 May 03;11:659253
pubmed: 34012921

Auteurs

Bruktawit Maru (B)

Department of Pharmacology and Therapeutics, McGill University, Montreal, QC, Canada.

Alessandra Messikommer (A)

Department of Chemistry, University of Zurich, Zurich, Switzerland.

Linhui Huang (L)

Department of Pharmacology and Therapeutics, McGill University, Montreal, QC, Canada.

Katja Seipel (K)

Department of Medical Oncology, Inselspital, Bern University Hospital, Bern, Switzerland.

Olivia Kovecses (O)

Department of Pharmacology and Therapeutics, McGill University, Montreal, QC, Canada.

Peter J M Valk (PJM)

Department of Hematology, Erasmus University Medical Center, Rotterdam, the Netherlands.

Alexandre P A Theocharides (APA)

Department of Medical Oncology and Hematology, University of Zurich and University Hospital Zurich, Zurich, Switzerland.

Francois E Mercier (FE)

Division of Hematology and Experimental Medicine, Department of Medicine, McGill University, Montreal, QC, Canada.

Thomas Pabst (T)

Department of Medical Oncology, Inselspital, Bern University Hospital, Bern, Switzerland.

Maureen McKeague (M)

Department of Pharmacology and Therapeutics, McGill University, Montreal, QC, Canada; Department of Chemistry, McGill University, Montreal, QC, Canada. Electronic address: maureen.mckeague@mcgill.ca.

Nathan W Luedtke (NW)

Department of Pharmacology and Therapeutics, McGill University, Montreal, QC, Canada; Department of Chemistry, University of Zurich, Zurich, Switzerland; Department of Chemistry, McGill University, Montreal, QC, Canada. Electronic address: nathan.luedtke@mcgill.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › PARP-1 improves leukemia outcomes by inducing...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Mort cellulaire › Mort cellulaire régulée › Apoptose › PARP-1 improves leukemia outcomes by inducing...
questionsmedicales.fr › Cellules › Cellules cultivées › Lignée cellulaire › PARP-1 improves leukemia outcomes by inducing...
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Leucémies › PARP-1 improves leukemia outcomes by inducing...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › PARP-1 improves leukemia outcomes by inducing...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › Inhibiteurs de poly(ADP-ribose) polymérases › PARP-1 improves leukemia outcomes by inducing...